Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Definitive Healthcare (Nasdaq: DH) announced inducement awards for two newly hired senior leaders. The company granted 172,414 time-based restricted stock units (RSUs) to Kate Hastings, the new Chief Customer Officer, and 1,018,330 RSUs to Benjamin Graboske, the new EVP, Technology, Engineering and Chief Data Officer, both effective March 3, 2025.

The awards, granted under Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan, feature a vesting schedule where 25% vests initially (February 1, 2026 for Hastings; April 1, 2026 for Graboske), with the remainder vesting quarterly at 6.25% over three years, subject to continued employment.

Positive

• Strategic executive hires in key positions (CCO and CDO)
• Substantial equity compensation aligning management interests with shareholders

Negative

• Potential future dilution from 1.19M new RSUs

FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare’s new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units (“RSUs”) effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare’s new EVP, Technology, Engineering and Chief Data Officer an inducement award consisting of 1,018,330 time-based RSUs, effective March 3, 2025. Each of these awards was individually negotiated and was granted as an inducement material to Ms. Hastings’ and Mr. Graboske’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant.

Ms. Hastings’ RSUs will vest as follows, subject to Ms. Hastings’ continued employment through each such date: (i) 25% will vest on February 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested.

Mr. Graboske’s RSUs will vest as follows, subject to Mr. Graboske’s continued employment through each such date: (i) 25% will vest on April 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com 
646-277-1251

Media Contact:
Bethany Swackhamer
bswackhamer@definitivehc.com 

FAQ

How many RSUs did Definitive Healthcare (DH) grant to its new Chief Customer Officer?

Definitive Healthcare granted 172,414 time-based RSUs to Kate Hastings, the new Chief Customer Officer, effective March 3, 2025.

What is the vesting schedule for Benjamin Graboske's RSU grant at DH?

25% of Graboske's 1,018,330 RSUs vest on April 1, 2026, with the remaining 75% vesting quarterly at 6.25% over three years.

When will Kate Hastings' RSUs begin vesting at Definitive Healthcare (DH)?

The first 25% of Hastings' RSUs will vest on February 1, 2026, with subsequent quarterly vesting of 6.25% over three years.

Under which regulatory rule were DH's inducement awards granted?

The inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and Definitive Healthcare's 2023 Inducement Plan.